Sonis Photography / Shutterstock.com
24 December 2024NewsAmericasMarisa Woutersen

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Massachusetts medical research company is awarded damages following a jury verdict that found a Japanese pharma had infringed on its patent | Patent relates to Duchenne muscular dystrophy treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).

More on this story

Americas
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).

More on this story

Americas
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).